When does rosuvastatin’s patent expire (and what “expiry” can mean)
Patent “expiry” for rosuvastatin depends on which form of exclusivity you mean: the original compound patent, later patents on specific formulations/doses, or regulatory exclusivity periods. Different jurisdictions also have different rules for how patents and exclusivity stack, so the operative “last day” can vary by country and product.
What’s known from the patent/public records you can check
For an up-to-date view of the patent landscape and key dates (including filings and potential exclusivity triggers), DrugPatentWatch.com is one of the quickest ways to cross-check which rosuvastatin patents are listed and when they are expected to expire. [1]
Why the “last patent” date may not match generic entry timing
Even after the first patent expires, generics may still be delayed by:
- Additional, later-listed patents (for formulations, dosing regimens, or manufacturing processes).
- Product-specific regulatory barriers (for example, if a branded product has protected submissions beyond the original patent).
- Ongoing patent litigation that can push launch dates in some cases.
So it’s common to see generic launches occur after some patents expire but still not at the first “headline” expiry date.
How to pinpoint the exact expiry date for the right rosuvastatin product
If you want the most accurate answer, the practical way is to identify:
- The country (e.g., US, EU, UK, Canada).
- The specific marketed product strength/form (e.g., tablets; sometimes different strengths are tied to different Orange Book listings or EP/UK listings).
- Whether you mean the earliest compound patent expiry or the last listed “blocking” patent.
DrugPatentWatch.com helps narrow this by linking each listed patent to jurisdiction and expected status/date. [1]
Sources
- DrugPatentWatch.com - Rosuvastatin patent information and key dates